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Background/aim: This study aimed to comparatively analyze the expression levels of the SLC1A1 gene in renal specimens from tumors
and adjacent healthy kidney tissues of patients with clear cell renal cell carcinoma (ccRCC).
Material and methods: Nineteen patients diagnosed with ccRCC were included in the study. The expression levels of the SLC1A1 and
GAPDH genes were measured in tumor and formalin-fixed paraffin-embedded (FFPE) tissue specimens from the adjacent healthy
kidney of each subject. Via the GEPIA database, the distribution of SLC1A1 gene expressions in ccRCC and healthy kidney tissues was
obtained. The relative expression of SLC1A1 was evaluated for the association with the clinical parameters of the patients.
Results: The expression of the SLC1A1 gene was significantly higher in males than females (P = 0.029). Also, there were statistically
significant associations between stages II–IV and Fuhrman grades 2–4 with respect to SLC1A1 gene expression (P < 0.001 for both).
Moreover, low levels of red blood cell and hemoglobin counts were significantly associated with the SLC1A1 expression (P < 0.001 and
P = 0.005, respectively). The expression of the SLC1A1 gene in tumor tissues increased approximately 3 times compared with normal
kidney tissues (P < 0.05). According to the GEPIA database, SLC1A1 gene expression is significantly higher in ccRCC patients than
healthy persons (P = 0.01).
Conclusion: The change in the expression of SLC1A1 may be crucial for ccRCC pathophysiology.
Key words: Glutamate transporter, SLC1A1, oncogene, renal cell carcinoma

1. Introduction
Renal cell carcinoma (RCC) is different from kidney
cancer with the involvement of the renal pelvis or renal
medullary and it is also the only type of cancer that occurs
in cells (renal tubules) that extend into the kidney bed.
RCC includes a range of heterogeneous cancers arising
from renal tubular cells. RCC is the third most common
cause of death after prostate and bladder cancer among
the urological cancers and accounts for about 2% of all
adult cancer patients. Moreover, its clinical course is the
most fatal one among urological cancers. RCC is caused
by the accumulation of numerous genetic and epigenetic
alterations similar to other cancer types (1).
Clear cell renal cell carcinomas (ccRCCs) are
ordinarily globular masses that may originate anywhere
in the renal cortex and frequently extrude beyond
the normal form of the kidney. Often, ccRCC attacks
the renal venous system, sometimes filling the renal
vein and growing longer into the vena cava or even

the right atrium. It is by far the most frequent type of
kidney cancer in adults (2).
In the last twenty years, genetic and clinical studies have
presented that ccRCC is both heterogeneous in its histology
and clinical course and heterogeneous in its genetic changes
(3). The identification of various histological subtypes of
ccRCC ensures a better comprehension of the molecular
mechanism of these distinct subtypes of cancer and one
or more crucial mutations have been defined for each
subtype (4). Sporadic cancers originate from multiple (epi)
genetic alterations. Therefore, promoter hypermethylation
of genes is considered to be involved in sporadic or
hereditary forms of ccRCC. The epigenetic alterations
that regulate the formation and progression of ccRCC
have not been fully revealed yet and are still in their early
stages of investigation (5). A more detailed specification of
epigenetically changed genes and pathways in ccRCC may
lead to the development of new and minimally invasive
diagnostic and prognostic tools for ccRCC. For the future,
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epigenetic therapies may provide an additional treatment
preference for advanced ccRCC that does not respond to
standard therapy (5). Factors that are potentially related
to the pathophysiology of ccRCC and probably usable as
biomarkers in the development of the disease need to be
investigated.
The SLC1A1 gene encodes a member of the highaffinity glutamate transporters that function to transport
glutamate across plasma membranes. A negatively charged
nonessential amino acid, glutamate has been broadly
investigated for its function in the central nervous system
as a neurotransmitter. Recently, an arising function for
metabolic flux and glutamate signaling in cancer has
been put forward by in vitro studies. The inhibition of
extracellular glutamate binding to ionotropic glutamate
receptors (GluRs) impedes the development of many types
of cancer, including breast cancer, via apoptosis activation,
cell division inhibition, and cell motility reduction.
Moreover, intracellular glutamate can be utilized to
generate ATP and macromolecules in order to assist
cancer cell proliferation and it is necessary for glutathione
(GSH) synthesis. Comprehensive studies have focused on
glutamine uptake and catabolism (through glutaminase)
as the primary source of intracellular glutamate in cancer
cells. The metabolic flux of glutamine to glutamate is
mediated by oncogenes like RAS and MYC. In spite of
the interest in glutamine-glutamate flux as a regulator of
the metabolic switch in cancer, limited data exist on the
expression and role of glutamate transporters in ccRCC
(6).
This study aimed to comparatively analyze the
expression levels of the SLC1A1 gene in renal specimens
from tumors and the adjacent healthy kidney tissues of
patients with ccRCC and to correlate them with clinical
data of patients.
2. Materials and methods
2.1. Patient selection
The study included 19 patients who applied to the Urology
Clinic of the Faculty of Medicine at Ondokuz Mayıs
University (OMU) between June 2016 and June 2017 for
the first time. The inclusion criteria for patient selection
were diagnosis with ccRCC and tumor resection with
radical nephrectomy. The exclusion criteria included the
status of having a tumor measuring 5 mm or less (papillary
adenoma); having chronic leukemia or lymphoma,
inflammatory disease, or autoimmune disease; receiving
neoadjuvant or adjuvant therapy; having other coexisting
subtypes of RCC; and a previous history of RCC. The
number of patients to be included in the study was detected
with a test power of 80% and a confidence interval of
95%. The statistically significant number of patients was
calculated as at least 19.
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Histopathological examination was performed on the
tumor tissue and some of the healthy kidney tissues around
this tumor resected by radical nephrectomy. Formalinfixed paraffin-embedded (FFPE) tissues were stored as
archival tissues and kept at room temperature at the
Department of Pathology. The results of histopathological
and radiological examinations of the patients were used
for the diagnosis of ccRCC. The 2012 Vancouver Renal
Neoplasia Classification of the International Society
of Urological Pathology was used for the histological
classification of renal tumors of the patients.
The Clinical Investigation Ethics Committee of OMU
approved the study and written informed consent was
received from the subjects participating in the study
(Approval No: 2016/139).
2.2. RNA isolation from FFPE tissues
Excess paraffin was removed from over the tumor and
the adjacent healthy kidney FFPE tissue specimens
of each subject in the archive. Then 3 or 4 sections of 5
µm in thickness were taken using a microtome (Leica
Microsystems, Nussloch, Germany) and transferred to
sterile 1.5-mL microcentrifuge tubes. The miRNeasy FFPE
Kit (QIAGEN GmbH, Hilden, Germany) was used for the
total RNA isolation from FFPE tissue sections.
2.3. cDNA synthesis and measurement of cDNA concentration
The obtained RNA samples were converted to cDNA by
reverse transcription using the Ipsogen RT Kit (QIAGEN).
The cDNA samples were stored at –20 °C until real-time
polymerase chain reaction (RT-PCR) was performed.
The spectrophotometric method was used to determine
the quality and concentration of the cDNA samples
obtained before RT-PCR experiments. This analysis
was performed using a microplate spectrophotometer
(Multiscan GO, Thermo Scientific, USA).
2.4. Gene expression analysis
The RT-PCR method was used for gene expression analysis
and Rotor Gene Q (QIAGEN) was used for this purpose.
A primer pair specific to the SLC1A1 gene was used
in the expression analysis, which was the Hs_SLC1A1_1_
SG QuantiTect Primer Assay (QIAGEN). As an internal
control, the housekeeping GAPDH gene and the primer
pair specific to it (Hs_GAPDH_1_SG QuantiTect Primer
Assay) (QIAGEN) was used. RT2 SYBR® Green qPCR
Mastermix (QIAGEN) was used as premix for the gene
expression analysis.
2.5. GEPIA database analysis
The distribution of SLC1A1 gene expressions in ccRCC
and healthy kidney tissues according to TCGA normal
and GTEx data was schematized by the GEPIA database
(7). Also, the list of most differential survival genes in
ccRCC was generated by using the GEPIA database in
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order to see the order of the SLC1A1 gene with respect to
the differential survival association in ccRCC.
2.6. Statistical analysis
Tumor samples from patients with RCC were compared
with the healthy tissue in the periphery of the tumor
tissue of the same patient. Using the Ct values obtained
from these tissues, the expression levels of the respective
genes were compared statistically. In the method based on
partial quantities, the measured values of the expression
measurement genes were normalized by GAPDH
transcription. For the comparison, Ct values were obtained
and the 2–ΔΔCt formula were used:
2–ΔΔCt = 2–[Tumor ΔCt (Gene – Reference) – Control ΔCt (Gene – Reference)] (1)
The 2–ΔCt formula was used to calculate gene expression
levels separately for the tumor and the adjacent healthy
kidney tissue. Using this formula, the fold changes in the
expression of genes in the tumor and the adjacent healthy
kidney tissue relative to the reference gene were calculated
separately. Statistical analysis of the significance of fold
changes in gene expression levels obtained from this
formula was then performed.
(2)
2–ΔCt = 2–[Tumor ΔCt (Gene – Reference)]
(3)
2–ΔCt = 2–[Control ΔCt (Gene – Reference)]

All statistical analyses were performed using SPSS 21
(IBM Corp., Armonk, NY, USA). Normal distribution
of data was evaluated statistically by the Kolmogorov–
Smirnov test. It was decided to use nonparametric tests
because the data were not suitable for normal distribution
(P < 0.05) and the number of samples was below 30. The
Wilcoxon signed-rank test was used in binary comparisons
and the Kruskal–Wallis test was applied in multiple
comparisons. P < 0.05 was accepted as a statistically
significant value and the evaluation was made at 0.95
confidence interval.
3. Results
The expression levels of the SLC1A1 gene in tumor tissues
and the healthy kidney tissues surrounding the tumors of 19
ccRCC patients were compared and possible associations
between the clinical parameters of the patients and gene
expression levels were investigated.
Demographic (sex, age) and clinicopathological
(TNM staging, Fuhrman nuclear grade, red blood cell
(RBC) count, hemoglobin count) characteristics of the
patients enrolled in this study are presented in Table 1.
The expression of the SLC1A1 gene was significantly
higher in males than females (P = 0.029). Also, there were

Table 1. Demographic and clinicopathological characteristics of patients and the statistical significance of
the associations of these data with SLC1A1 gene expressions of the patients
Patients (n = 19)
Sex

Age

TNM staging

Fuhrman nuclear grade

RBC count

Hemoglobin count

Male

9 (47.4%)

Female

10 (52.6%)

35–44

4 (21%)

45–64

10 (52.7%)

>65

5 (26.3%)

Stage I

13 (68.4%)

Stage II

3 (15.8%)

Stage III

1 (5.3%)

Stage IV

2 (10.5%)

Grade 2

13 (68.4%)

Grade 3

2 (10.5%)

Grade 4

4 (21.1%)

Low

4 (21%)

Normal

14 (73.7%)

High

1 (5.3%)

Low

7 (36.8%)

Normal

12 (63.2%)

P-value
0.029

0.584

<0.001 (between stage II and IV)

<0.001 (between grade 2 and 4)

<0.001 (between low and normal
RBC count)
0.005 (between low and normal
hemoglobin count)

TNM: Tumor-Node-Metastasis. RBC count lower than 4 million/mm3 and hemoglobin count lower than
13 g/dL were considered as low.
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statistically significant associations between stages II–IV
and Fuhrman grades 2–4 with respect to SLC1A1 gene
expressions (P < 0.001 for both). Moreover, low levels
of RBC and hemoglobin counts, which were parameters
giving information about the occurrence of ccRCC, are
significantly associated with SLC1A1 expression (P <
0.001 and P = 0.005, respectively).
Tumor samples of patients with ccRCC were
compared with healthy kidney tissues around the tumor
of the same patient with respect to the expression levels
of the SLC1A1 gene (Figures 1 and 2). The expression
of the SLC1A1 gene in kidney tumor tissues increased
approximately 3 times compared with normal kidney
tissues. As shown in Figures 1 and 2, the change in the
expression levels of the SLC1A1 gene between the tumor
and normal kidney tissues was statistically significant (P
< 0.05).
According to the GEPIA database, which is based on
TCGA normal and GTEx data of 523 ccRCC patients
and 100 healthy persons, SLC1A1 gene expression is
significantly higher in ccRCC patients when compared
with healthy persons (P = 0.01) (Figure 3). As can be
seen, both the present study and the GEPIA database
show significantly increased levels of SLC1A1 gene
expression in ccRCC cases when compared with healthy
control cases. In other words, the outcomes of the GEPIA
database support our findings.
Lastly, a list of genes was extracted as the most
differential survival genes in ccRCC according to the
GEPIA database (Table 2). SLC1A1 was one of these
genes. This shows a significant relationship of SLC1A1
and supports our findings.

4. Discussion
Renal cell carcinoma is one of the 15 most frequent types
of cancer arising globally. The most aggressive subtype,
ccRCC comprises about 70% of all kidney tumors. ccRCC is
potentially treatable by resection. However, approximately
30% of patients show recurrence after the first nephrectomy.
Unfortunately, ccRCC is often nonsymptomatic in the
early stages and is frequently reported in the advanced
phase with metastases. In the case of metastasis, ccRCC
is radiation- and chemoresistant and remains incurable in
most cases, resulting in a mortality rate of 95%. To date,
no effective ccRCC therapy has been created and none of
the probable biomarkers have been approved for clinical
administration (8).
In this study, tumor tissues of the patients with ccRCC
were compared with healthy kidney tissues around the
tumor tissues of the same patients in terms of the expression
levels of the SLC1A1 gene and possible associations
between the clinical parameters of the patients and gene
expression levels were analyzed.
According to the association analysis between
demographic (sex, age) and clinicopathological (TNM
staging, Fuhrman nuclear grade, RBC count, hemoglobin
count) parameters and the expression level of the SLC1A1
gene, interesting results were obtained. The expression of
the SLC1A1 gene was significantly higher in males than in
females (P = 0.029). Also, there were statistically significant
associations between stages II–IV and Fuhrman grades
2–4 with respect to SLC1A1 gene expression (P < 0.001
for both). Moreover, low levels of RBC and hemoglobin
counts, which were parameters giving information about
the occurrence of ccRCC, are significantly associated with

Figure 1. Quantitative expression levels of the SLC1A1 gene in tumor tissues as
compared with adjacent healthy kidney tissues of patients with ccRCC (P < 0.05).
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Figure 2. Distribution of patients’ quantitative expression levels
of the SLC1A1 gene in tumor tissues as compared to adjacent
healthy kidney tissues.

SLC1A1 expression (P < 0.001 and P = 0.005, respectively).
Most studies in the literature support our findings with
respect to the relationship of SLC1A1 expression in ccRCC
with anemia. Anemia is a condition in which individuals
have insufficient healthy RBCs to carry adequate
oxygen to tissues in the body. According to a study that
retrospectively reviewed 204 patients diagnosed with
ccRCC between 1995 and 2008 in a community hospital
setting, anemia can precede the diagnosis of ccRCC.
Upon the exclusion of the measurement of hemoglobin

Figure 3. Distribution of SLC1A1 gene expressions in ccRCC and
healthy kidney tissues according to TCGA normal and GTEx
data in GEPIA database (P = 0.01).

levels from the study, the severity of anemia corresponds
to poorer overall survival of ccRCC patients (9). On the
contrary, it is known that kidney cancer cells can release a
hormone called erythropoietin. This hormone causes the
bone marrow to produce too many RBCs. In other tissues,
especially in cancer cells, it inhibits apoptosis, stimulates
angiogenesis, and promotes cell proliferation. Many studies
have confirmed the overexpression of erythropoietin and
its receptor in clear cell renal carcinoma (10).

Table 2. The list of most differential survival genes in ccRCC according to GEPIA database.
Gene symbol

Gene ID

P-value (overall survival)

PEBP1P2

ENSG00000270532.1

1.85e-14

RP11-379F4.8

ENSG00000271778.1

3.42e-14

SOWAHB

ENSG00000186212.3

1.84e-13

CPT2

ENSG00000157184.5

1.92e-13

WDR72

ENSG00000166415.14

2.25e-13

DHRS12

ENSG00000102796.10

1.30e-12

TOLLIP

ENSG00000078902.15

1.44e-12

TPRG1L

ENSG00000158109.14

1.59e-12

BAG1

ENSG00000107262.16

3.58e-12

SLC1A1

ENSG00000106688.11

5.68e-12
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Tumor samples of patients with ccRCC were compared
with healthy kidney tissues around the tumor of the same
patient with respect to the expression level of the SLC1A1
gene. The expression of the SLC1A1 gene in kidney tumor
tissues increased approximately 3 times compared with
normal kidney tissues, which was statistically significant.
Also, according to the GEPIA database, which is based
on TCGA normal and GTEx data of 523 ccRCC patients
and 100 healthy persons, SLC1A1 gene expression is
significantly higher in ccRCC patients when compared
with healthy persons in correlation with our wet-lab
experiments. The studies in the literature seem to support
our results. A study investigating signaling through
glutamate receptors in human cancers showed that
increased activity of hypoxia-inducible factors (HIFs)
due to hypoxia or von Hippel–Lindau (VHL) loss-offunction in ccRCC augmented the release of glutamate,
which was mediated by HIF-dependent expression of
the SLC1A1 and SLC1A3 genes encoding glutamate
transporters (11). When looking at the association
between SLC1A1 and cancer types other than ccRCC,
a significant correlation was observed between SLC1A1
overexpression and glioma. According to this association,
the uptake of neurotransmitter glutamate is affected
primarily by transporters expressed on astrocytes, and
the downregulation of these transporters leads to seizures
and neuronal death. Neurons also express a glutamate
transporter, excitatory amino acid carrier-1 (SLC1A1),
but the physiological function of this transporter remains
uncertain. In a study conducted on C6 rat glioma cells, a
line described to contain neural stem-like cells, SLC1A1
was markedly induced by all-trans retinoic acid (ATRA), a
well-known differentiating agent. After 4 days of treatment
with 10 µM ATRA, SLC1A1 mRNA was increased by
400% compared with the control, and the C6 culture
was greatly enriched of cells with bipolar morphology
strongly positive for SLC1A1 immunoreactivity. Thus,
the increased expression of SLC1A1 was correlated with
the differentiation of glioma (12). In another study,
genetically SLC1A1-null (Slc1a1−/−) mice had reduced

levels of neuronal glutathione and, with aging, developed
brain atrophy and behavioral changes. Therefore, SLC1A1knockout mice exhibit increased oxidative stress due
to GSH depletion (13). Also, a study conducted with 68
patients with renal tumors and 30 age-matched normal
controls detected significantly increased reactive oxygen
species and nitric oxide and decreased glutathione
in patients with renal cell carcinoma compared with
normal subjects (14). When we evaluate these two studies
together, it is possible to infer that ccRCC causes oxidative
stress and shows this effect via increased levels of SLC1A1
expression.
A list of genes was extracted as the most differential
survival genes in ccRCC according to the GEPIA database
and SLC1A1 was seen as one of these genes. This also
supports significant associations between SLC1A1 and
ccRCC, as in our results.
In conclusion, the changes in the expression levels of
the genes analyzed and RCC-specific parameters need to
be confirmed in larger study groups. If verified, it may
be possible to use the expression changes of SLC1A1 as
biomarkers for the prognosis of ccRCC. The results of
this study may suggest that molecular applications can be
designed to change the level of the expression of SLC1A1
to affect the development of ccRCC in future projects.
As the limitations of the study, perhaps the greatest
source of complexity and variability in gene expression
experiments stems from phenomena not related to
treatment, or intrinsic variability, which is hard to control
and reproduce. Normal fluctuations in gene expression
will occur as a result of differences in age, sex, temperature,
light, diet, and hormonal status. Although age, sex,
and the external environment can be tightly controlled
within experiments, comparisons between laboratories
using similar protocols may be more challenging
when environmental factors are not strictly controlled.
Differences in nutritional or hydration status, time of last
meal, hormonal fluctuations during estrus, and seasonal
and light-induced changes in hormone levels are more
difficult to control within experiments.
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